ArticleJournal of the American Heart Association2024
Combined Prognostic Impact of Low Muscle Mass and Hypoalbuminemia in Patients Hospitalized for Heart Failure: A Retrospective Cohort Study.
Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Combined Prognostic Value of the PROFUND Index and Serum Albumin for One-Year Mortality in Elderly Patients with Acute Heart Failure.Journal of clinical medicine · 2026Article
- A Sensitive Multichannel Fluorescent Polymer Sensor Array for the Detection of Protein Fluctuations in Serum.Sensors (Basel, Switzerland) · 2026Article
- A comparative study of intravenous polymyxin B and colistimethate sodium on efficacy, safety, and cost comparison in treating pulmonary infections: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Edentulism as an independent risk factor for sarcopenia: evidence from cross-sectional and longitudinal analyses based on the CHARLS cohort.BMC oral health · 2025Article
- Article
- Impact of the hemoglobin-to-red cell distribution width ratio on 30-day readmission in patients with heart failure.BMC cardiovascular disorders · 2025Article
- Article
- Article
- Impact of chest computed tomography-determined low skeletal muscle mass on the survival of patients with acute heart failure.Frontiers in cardiovascular medicine · 2025Article
- Prognostic impact of CONUT score in older patients with chronic heart failure.BMC geriatrics · 2024Article
- Prognostic value of alkaline phosphatase-to-albumin ratio in critically ill patients with atrial fibrillation: A MIMIC-IV retrospective study.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSarcopenia and hypoalbuminemia have been identified as independent predictors of increased adverse outcomes, including mortality and readmissions, in hospitalized older adults with acute decompensated heart failure (ADHF). However, the impact of coexisting sarcopenia and hypoalbuminemia on morbidity and death in adults with ADHF has not yet been investigated. We aimed to investigate the combined effects of lower muscle mass (LMM) as a surrogate for sarcopenia and hypoalbuminemia on in-hospital and postdischarge outcomes of patients hospitalized for ADHF. METHODS AND
resultsA total of 385 patients admitted for ADHF between 2017 and 2020 at a single institution were retrospectively identified. Demographic and clinical data were collected, including serum albumin levels at admission and discharge. Skeletal muscle indices were derived from semi-automated segmentation software analysis on axial chest computed tomography at the twelfth vertebral level. Our analysis revealed that patients who had LMM with admission hypoalbuminemia experienced increased diagnoses of infection and delirium with longer hospital length of stay and more frequent discharge to a facility. Upon discharge, 27.9% of patients had higher muscle mass without discharge hypoalbuminemia (reference group), 9.7% had LMM without discharge hypoalbuminemia, 38.4% had higher muscle mass with discharge hypoalbuminemia, and 24.0% had LMM with discharge hypoalbuminemia; mortality rates were 37.6%, 51.4%, 48.9%, and 63.2%, respectively. 1- and 3-year mortality risks were highest in those with LMM and discharge hypoalbuminemia; this relationship remained significant over a median 23.6 (3.1-33.8) months follow-up time despite multivariable adjustments (hazard ratio, 2.03 [95% CI, 1.31-3.16];
conclusionsHospitalization with ADHF, LMM, and hypoalbuminemia portend heightened mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.